These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36370741)

  • 1. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial.
    Litwin AH; Lum PJ; Taylor LE; Mehta SH; Tsui JI; Feinberg J; Kim AY; Norton BL; Heo M; Arnsten J; Meissner P; Karasz A; Mckee MD; Ward JW; Johnson N; Pericot-Valverde I; Agyemang L; Stein ES; Thomas A; Borsuk C; Blalock KL; Wilkinson S; Wagner K; Roche J; Murray-Krezan C; Anderson J; Jacobsohn V; Luetkemeyer AF; Falade-Nwulia O; Page K;
    Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1112-1127. PubMed ID: 36370741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study.
    Heo M; Norton BL; Pericot-Valverde I; Mehta SH; Tsui JI; Taylor LE; Lum PJ; Feinberg J; Kim AY; Arnsten JH; Sprecht-Walsh S; Page K; Murray-Krezan C; Anderson J; Litwin AH;
    J Hepatol; 2024 May; 80(5):702-713. PubMed ID: 38242324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
    Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
    Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ;
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):153-161. PubMed ID: 29310928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study.
    Litwin AH; Jost J; Wagner K; Heo M; Karasz A; Feinberg J; Kim AY; Lum PJ; Mehta SH; Taylor LE; Tsui JI; Pericot-Valverde I; Page K;
    Contemp Clin Trials; 2019 Dec; 87():105859. PubMed ID: 31669450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shame and stigma in association with the HCV cascade to cure among people who inject drugs.
    Batchelder AW; Heo M; Foley JD; Sullivan MC; Lum P; Pericot Valverde I; Taylor LE; Mehta SH; Kim AY; Norton B; Tsui JI; Feinberg J; Page K; Litwin AH;
    Drug Alcohol Depend; 2023 Dec; 253():111013. PubMed ID: 37951006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care.
    Norton BL; Akiyama MJ; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Int J Drug Policy; 2021 Jul; 93():103135. PubMed ID: 33667826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
    Bouscaillou J; Kikvidze T; Butsashvili M; Labartkava K; Inaridze I; Etienne A; Le Pluart D; Kamkamidze G; Gamezardashvili A; Kharshiladze D; Avril E; Luhmann N
    Int J Drug Policy; 2018 Dec; 62():104-111. PubMed ID: 30384026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs.
    Heo M; Pericot-Valverde I; Rennert L; Akiyama MJ; Norton BL; Gormley M; Agyemang L; Arnsten JH; Litwin AH
    Clin Infect Dis; 2021 Dec; 73(11):2093-2100. PubMed ID: 33876230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
    Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
    Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study.
    Lopes SS; Pericot-Valverde I; Lum PJ; Taylor LE; Mehta SH; Tsui JI; Feinberg J; Kim AY; Norton BL; Page K; Murray-Krezan C; Anderson J; Karasz A; Arnsten J; Moschella P; Heo M; Litwin AH
    BMC Infect Dis; 2024 Feb; 24(1):251. PubMed ID: 38395747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in alcohol use during hepatitis C treatment in persons who inject drugs.
    Martin M; Roth PJ; Niu J; Pericot-Valverde I; Heo M; Padi A; Norton BL; Akiyama MJ; Litwin AH
    J Viral Hepat; 2022 Nov; 29(11):1004-1014. PubMed ID: 35997620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
    Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
    BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
    Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
    Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs.
    Tsui JI; Lum PJ; Taylor LE; Mehta SH; Feinberg J; Kim AY; Norton BL; Niu J; Heo M; Arnsten J; Pericot-Valverde I; Thomas A; Blalock KL; Radick A; Murray-Krezan C; Page K; Litwin AH;
    Drug Alcohol Depend; 2023 Jun; 247():109878. PubMed ID: 37150144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.
    Solomon SS; Wagner-Cardoso S; Smeaton L; Sowah LA; Wimbish C; Robbins G; Brates I; Scello C; Son A; Avihingsanon A; Linas B; Anthony D; Nunes EP; Kliemann DA; Supparatpinyo K; Kityo C; Tebas P; Bennet JA; Santana-Bagur J; Benson CA; Van Schalkwyk M; Cheinquer N; Naggie S; Wyles D; Sulkowski M
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):307-317. PubMed ID: 35026142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.